|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM236 |
Gene summary for TMEM236 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM236 | Gene ID | 653567 |
| Gene name | transmembrane protein 236 | |
| Gene Alias | FAM23A | |
| Cytomap | 10p12.33 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q5W0B7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 653567 | TMEM236 | HTA11_347_2000001011 | Human | Colorectum | AD | 4.89e-14 | 6.97e-01 | -0.1954 |
| 653567 | TMEM236 | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.99e-02 | -2.86e-01 | 0.0674 |
| 653567 | TMEM236 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 5.44e-09 | -3.28e-01 | 0.294 |
| 653567 | TMEM236 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 8.65e-06 | -3.09e-01 | 0.3859 |
| 653567 | TMEM236 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 5.99e-08 | -3.30e-01 | 0.3005 |
| 653567 | TMEM236 | A001-C-207 | Human | Colorectum | FAP | 1.67e-04 | -2.78e-01 | 0.1278 |
| 653567 | TMEM236 | A015-C-203 | Human | Colorectum | FAP | 3.76e-03 | -1.86e-01 | -0.1294 |
| 653567 | TMEM236 | A002-C-201 | Human | Colorectum | FAP | 7.54e-10 | -3.02e-01 | 0.0324 |
| 653567 | TMEM236 | A001-C-119 | Human | Colorectum | FAP | 3.31e-02 | -2.49e-01 | -0.1557 |
| 653567 | TMEM236 | A001-C-108 | Human | Colorectum | FAP | 2.06e-04 | -2.67e-01 | -0.0272 |
| 653567 | TMEM236 | A002-C-205 | Human | Colorectum | FAP | 5.07e-09 | -2.85e-01 | -0.1236 |
| 653567 | TMEM236 | A015-C-006 | Human | Colorectum | FAP | 3.65e-09 | -3.39e-01 | -0.0994 |
| 653567 | TMEM236 | A002-C-114 | Human | Colorectum | FAP | 7.54e-04 | -1.63e-01 | -0.1561 |
| 653567 | TMEM236 | A015-C-104 | Human | Colorectum | FAP | 3.52e-03 | -1.53e-01 | -0.1899 |
| 653567 | TMEM236 | A002-C-016 | Human | Colorectum | FAP | 2.04e-02 | -2.16e-01 | 0.0521 |
| 653567 | TMEM236 | A015-C-002 | Human | Colorectum | FAP | 2.42e-05 | -3.10e-01 | -0.0763 |
| 653567 | TMEM236 | A002-C-116 | Human | Colorectum | FAP | 2.85e-05 | -1.21e-01 | -0.0452 |
| 653567 | TMEM236 | A014-C-008 | Human | Colorectum | FAP | 1.41e-04 | -2.40e-01 | -0.191 |
| 653567 | TMEM236 | A018-E-020 | Human | Colorectum | FAP | 1.66e-03 | -1.09e-01 | -0.2034 |
| 653567 | TMEM236 | CRC-1-8810 | Human | Colorectum | CRC | 8.94e-11 | -3.25e-01 | 0.6257 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMEM236 | SNV | Missense_Mutation | novel | c.471N>T | p.Lys157Asn | p.K157N | Q5W0B7 | protein_coding | tolerated(0.37) | benign(0.387) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TMEM236 | SNV | Missense_Mutation | novel | c.4G>T | p.Ala2Ser | p.A2S | Q5W0B7 | protein_coding | tolerated(0.15) | benign(0.23) | TCGA-BH-A0W7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| TMEM236 | deletion | Frame_Shift_Del | novel | c.522delT | p.Val175Ter | p.V175* | Q5W0B7 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| TMEM236 | SNV | Missense_Mutation | novel | c.892N>A | p.Asp298Asn | p.D298N | Q5W0B7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
| TMEM236 | SNV | Missense_Mutation | novel | c.892N>A | p.Asp298Asn | p.D298N | Q5W0B7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A3HL-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| TMEM236 | SNV | Missense_Mutation | novel | c.176N>T | p.Ala59Val | p.A59V | Q5W0B7 | protein_coding | deleterious(0.01) | possibly_damaging(0.722) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| TMEM236 | SNV | Missense_Mutation | novel | c.757N>A | p.Arg253Ser | p.R253S | Q5W0B7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| TMEM236 | SNV | Missense_Mutation | novel | c.757N>T | p.Arg253Cys | p.R253C | Q5W0B7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| TMEM236 | SNV | Missense_Mutation | novel | c.61N>C | p.Ser21Pro | p.S21P | Q5W0B7 | protein_coding | tolerated(0.11) | possibly_damaging(0.804) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| TMEM236 | SNV | Missense_Mutation | novel | c.298N>T | p.Pro100Ser | p.P100S | Q5W0B7 | protein_coding | deleterious(0.02) | probably_damaging(0.99) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |